Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hangzhou Singclean Medical Products Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners. Both matters are located within 1 distinct art unit.
JOSEPH RICCI MATTHEWS is the busiest examiner, responsible for 1 pending office action. This means the 2 pending office actions are evenly divided, with each of the 2 distinct examiners handling one matter. The concentration in 1 distinct art unit suggests a consistent technical environment for both applications. Practitioners can benefit from the shared standards of a single art unit while managing two different examiner relationships.
Since JOSEPH RICCI MATTHEWS only handles 1 pending office action, the company must adapt to the individual styles of two different people. However, the unified art unit may provide a common ground for the technical arguments used in the Biotechnology & Pharmaceuticals sector. This structure allows for a balance between individual examiner preferences and a centralized technical strategy within a single department.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATTHEWS, JOSEPH RICCI | 1 | — | — |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18135733 | COLLAGEN AND SODIUM HYALURONATE CROSS-LINKED COMPOSITE FILLER FOR INJECTION AND PREPARATION METHOD THEREOF | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18650404 | METHOD FOR PREPARING LYOPHILIZED COLLAGEN POWDER AND USE THEREOF | MATTHEWS, JOSEPH RICCI | — | §103 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18135733 | COLLAGEN AND SODIUM HYALURONATE CROSS-LINKED COMPOSITE FILLER FOR INJECTION AND PREPARATION METHOD THEREOF | AUDET, MAURY A | 1654 | §103 | Final Rejection | — | Pending | Apr 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial